Irvine drug maker Allergan Inc. said Thursday that it signed a deal to develop a drug to treat a urinary disorder.
Allergan is paying $43 million to Serenity Pharmaceuticals LLC of Milford, Pa., for exclusive worldwide development, manufacturing and commercializing rights for Serenity’s Ser-120, which treats nocturia, or frequent urination at night.
Serenity also could receive potential development and milestone payments of up to $122 million.
The Serenity deal is one of several Allergan’s made in order to boost its urology offerings in recent years, along with testing flagship Botox for treating overactive bladder.
Allergan is working with Spectrum Pharmaceuticals Inc., also of Irvine, to develop EoQuin, a bladder cancer drug candidate that’s in late-stage clinical trials.
